2,976 reports of this reaction
3.2% of all GEMCITABINE HYDROCHLORIDE reports
#5 most reported adverse reaction
ANAEMIA is the #5 most commonly reported adverse reaction for GEMCITABINE HYDROCHLORIDE, manufactured by Armas Pharmaceuticals Inc.. There are 2,976 FDA adverse event reports linking GEMCITABINE HYDROCHLORIDE to ANAEMIA. This represents approximately 3.2% of all 92,220 adverse event reports for this drug.
Patients taking GEMCITABINE HYDROCHLORIDE who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among GEMCITABINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for GEMCITABINE HYDROCHLORIDE:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 2,976 FDA reports for GEMCITABINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 3.2% of all adverse event reports for GEMCITABINE HYDROCHLORIDE, making it a notable side effect.
If you experience anaemia while taking GEMCITABINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.